Onconetix (NASDAQ:ONCO) Major Shareholder Financial Lp Hrt Sells 53,867 Shares of Stock

Onconetix, Inc. (NASDAQ:ONCO) major shareholder Financial Lp Hrt sold 53,867 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $0.73, for a total value of $39,322.91. Following the transaction, the insider owned 143,185 shares of the company’s stock, valued at approximately $104,525.05. This trade represents a 27.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Monday, April 20th, Financial Lp Hrt sold 94,462 shares of Onconetix stock. The stock was sold at an average price of $0.75, for a total value of $70,846.50.
• On Friday, April 17th, Financial Lp Hrt purchased 34,636 shares of Onconetix stock. The shares were acquired at an average price of $0.73 per share, with a total value of $25,284.28.
• On Wednesday, April 15th, Financial Lp Hrt purchased 92,554 shares of Onconetix stock. The shares were acquired at an average price of $0.76 per share, with a total value of $70,341.04.
• On Tuesday, April 14th, Financial Lp Hrt purchased 74,350 shares of Onconetix stock. The shares were acquired at an average price of $0.77 per share, with a total value of $57,249.50.

Onconetix Stock Down 7.5%

Shares of ONCO stock opened at $0.68 on Wednesday. Onconetix, Inc. has a 12 month low of $0.66 and a 12 month high of $74.29. The firm has a market cap of $446,688.00, a PE ratio of 0.00 and a beta of 3.63. The stock has a 50 day moving average of $2.62 and a 200-day moving average of $8.51.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Onconetix stock. Pacific Capital Wealth Advisors Inc. purchased a new position in shares of Onconetix, Inc. (NASDAQ:ONCO) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned about 0.84% of Onconetix as of its most recent SEC filing. 23.89% of the stock is currently owned by institutional investors and hedge funds.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.